RDTI receipt, Advanced Overseas Finding
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The company has already received an initial R&D Tax Incentive instalment for the same financial year. Adalta's CEO highlighted that this finding supports their strategy of integrating overseas innovation with Australian capabilities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from AdAlta
- EW-001 JDC milestone approvals
- China Representative Office opens
- Date of AGM & Closing Date for Director Nominations
- US FDA grants EW-001 pre-IND meeting
- Oribiotech deal validates AdAlta manufacturing strategy
Later from AdAlta
- Quarterly Appendix 4C and Activities Report
- Change of AGM Date
- Letter to Shareholders, Notice of AGM & Proxy Form
- $1.4m additional RDTI refund
- EW-001 Orphan Drug Designation, pre-IND update
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta